The latest update is out from Faron Pharmaceuticals Oy ( (GB:FARN) ).
Faron Pharmaceuticals Ltd announced positive results from its Phase II BEXMAB trial, showing a high overall response rate in patients with higher-risk myelodysplastic syndrome (HR MDS) treated with bexmarilimab and azacitidine. The trial met its primary endpoint, demonstrating both safety and efficacy, and the company plans to proceed with a Phase III trial pending FDA feedback. This development positions Faron strongly in the field of HR MDS treatment, addressing a significant unmet need and potentially overcoming treatment resistance.
More about Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd is a global, clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat cancers. The company’s lead asset, bexmarilimab, is an anti-Clever-1 humanized antibody aimed at reprogramming myeloid cell function to remove cancer immunosuppression. Faron is dedicated to expanding the reach of immunotherapy by exploring innovative ways to harness the immune system’s power.
YTD Price Performance: 14.63%
Average Trading Volume: 23,929
Technical Sentiment Signal: Strong Sell
Current Market Cap: £266.6M
Learn more about FARN stock on TipRanks’ Stock Analysis page.